Laman UtamaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$4.34
Julat hari
$4.20 - $4.43
Julat tahun
$3.36 - $5.36
Permodalan pasaran
170.21J USD
Bilangan Purata
3.43K
Nisbah P/E
-
Hasil dividen
-
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CHF) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 4.48J | -16.15% |
Pendapatan bersih | -12.65J | -12.62% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.36 | -20.00% |
EBITDA | -12.44J | 14.47% |
Kadar cukai berkesan | -0.03% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CHF) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 93.06J | -37.73% |
Jumlah aset | 102.11J | -35.59% |
Jumlah liabiliti | 21.77J | 28.90% |
Jumlah ekuiti | 80.33J | — |
Syer tertunggak | 37.79J | — |
Harga kepada buku | 2.04 | — |
Pulangan pada aset | -29.56% | — |
Pulangan pada modal | -34.98% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CHF) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -12.65J | -12.62% |
Tunai daripada operasi | -11.15J | 15.49% |
Tunai daripada pelaburan | 11.95J | 365.95% |
Tunai daripada pembiayaan | -300.00K | -101.96% |
Perubahan bersih dalam tunai | 294.00K | 115.65% |
Aliran tunai bebas | -6.65J | -4.92% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
153
